Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147247 | 0.84 | KDM4E (0.32) | CYP1A2PDE2AKDM4EALDH1A1 | |
| SCHEMBL13028821 | 0.83 | LMNA (0.42) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL15218860 | 0.73 | LMNA (0.42) | LMNASMN1; SMN2L3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL8343522 | 0.73 | LMNA (0.45) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL6335574 | 0.72 | MEN1 (0.44) | LMNASMN1; SMN2L3MBTL1CYP1A2KDM4E | |
| SCHEMBL4595225 | 0.71 | LMNA (0.43) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL13983020 | 0.71 | TDP1 (0.44) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL10048775 | 0.71 | LMNA (0.43) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL4918384 | 0.71 | LOXL2 (0.44) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A | |
| SCHEMBL15752122 | 0.71 | LMNA (0.48) | LMNASMN1; SMN2L3MBTL1CYP1A2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-110003178-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| CN-105431420-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110003178-A | Two heteroaryl compounds and application thereof | 豪夫迈·罗氏有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| CN-105431420-A | Diheteroaryl compounds and uses thereof | HOFFMANN LA ROCHE | 2016-03-23 | — | — | CN | disclosed |
| EP-2991978-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche SA (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160052940-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | LMNA 917/4885SMN1; SMN2 51/4885L3MBTL1 1843/4885 |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | LMNA 917/4885SMN1; SMN2 51/4885L3MBTL1 1843/4885 |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | LMNA 917/4885SMN1; SMN2 51/4885L3MBTL1 1843/4885 |
| US-20160052940-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | LMNA 917/4885SMN1; SMN2 51/4885L3MBTL1 1843/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | LMNA 917/4885SMN1; SMN2 51/4885L3MBTL1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.